APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Acute Migraine Drugs

A migraine is an episodic and unpredictable headache disorder that presents with disabling attack. Migraine is one of the most frequent disabling neurological conditions with a major impact on the patient’s quality of life. Migraine has been described as a chronic disorder that characterized with attacks. Attacks are characterized by moderate–severe, often unilateral, pulsating headache attacks, typically lasting 4 to 72 hours.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

A migraine is an episodic and unpredictable headache disorder that presents with disabling attack. Migraine is one of the most frequent disabling neurological conditions with a major impact on the patient’s quality of life. Migraine has been described as a chronic disorder that characterized with attacks. Attacks are characterized by moderate–severe, often unilateral, pulsating headache attacks, typically lasting 4 to 72 hours.

Selected research

Industry Growth & Trends

Global Acute Migraine Drugs Industry Growth and Trends Forecast to 2032

1 January 202697 pages

Choose your research edition.

Industry ResearchAcute Migraine Drugs Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Acute Migraine Drugs Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Acute Migraine Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Acute Migraine Drugs Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Acute Migraine Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

A migraine is an episodic and unpredictable headache disorder that presents with disabling attack. Migraine is one of the most frequent disabling neurological conditions with a major impact on the patient’s quality of life. Migraine has been described as a chronic disorder that characterized with attacks. Attacks are characterized by moderate–severe, often unilateral, pulsating headache attacks, typically lasting 4 to 72 hours.

The top 3 manufacturers held about 29.5% of the market share in 2019, while top 5 hold 41.93%.

Report Scope

Read the full market overview

This report provides a structured, data-driven view of the global Acute Migraine Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Acute Migraine Drugs market size, estimates, and forecasts are presented in terms of sales volume (K Unit) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Acute Migraine Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Acute Migraine Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Acute Migraine Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Acute Migraine Drugs Market by Company

GSK

Teva

Pfizer

Novartis

Sun Pharma

Grunenthal

Endo Pharmaceuticals

Merck

J & J

Acute Migraine Drugs Segment by Type

Triptans

NSAIDs

Others

Acute Migraine Drugs Segment by Application

Hospital Pharmacies

Drug Stores

Acute Migraine Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acute Migraine Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Acute Migraine Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acute Migraine Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Acute Migraine Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Acute Migraine Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Triptans Table 2. Major Company of NSAIDs Table 3. Major Company of Others Table 4. Global Acute Migraine Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Acute Migraine Drugs Sales by Type (2021-2026) & (K Unit) Table 6. Global Acute Migraine Drugs Sales Market Share in Volume by Type (2021-2026) Table 7. Global Acute Migraine Drugs Sales by Type (2021-2026) & (US$ Million) Table 8. Global Acute Migraine Drugs Sales Market Share in Value by Type (2021-2026) Table 9. Global Acute Migraine Drugs Price by Type (2021-2026) & (USD/Unit) Table 10. Global Acute Migraine Drugs Sales by Type (2027-2032) & (K Unit) Table 11. Global Acute Migraine Drugs Sales Market Share in Volume by Type (2027-2032) Table 12. Global Acute Migraine Drugs Sales by Type (2027-2032) & (US$ Million) Table 13. Global Acute Migraine Drugs Sales Market Share in Value by Type (2027-2032) Table 14. Global Acute Migraine Drugs Price by Type (2027-2032) & (USD/Unit) Table 15. North America Acute Migraine Drugs Sales by Type (2021-2026) & (K Unit) Table 16. North America Acute Migraine Drugs Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Acute Migraine Drugs Sales by Type (2021-2026) & (K Unit) Table 18. Europe Acute Migraine Drugs Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Acute Migraine Drugs Sales by Type (2021-2026) & (K Unit) Table 20. Asia-Pacific Acute Migraine Drugs Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Acute Migraine Drugs Sales by Type (2021-2026) & (K Unit) Table 22. Latin America Acute Migraine Drugs Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Acute Migraine Drugs Sales by Type (2021-2026) & (K Unit) Table 24. Middle East and Africa Acute Migraine Drugs Sales by Type (2021-2026) & (US$ Million) Table 25. Acute Migraine Drugs Industry Trends Table 26. Acute Migraine Drugs Industry Drivers Table 27. Acute Migraine Drugs Industry Opportunities and Challenges Table 28. Acute Migraine Drugs Industry Restraints Table 29. Global Acute Migraine Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Acute Migraine Drugs Revenue Market Share by Company (2021-2026) Table 31. Global Acute Migraine Drugs Sales by Company (2021-2026) & (K Unit) Table 32. Global Acute Migraine Drugs Sales Share by Company (2021-2026) Table 33. Global Acute Migraine Drugs Market Price by Company (2021-2026) & (USD/Unit) Table 34. Global Acute Migraine Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Acute Migraine Drugs Major Company Production Sites and Headquarters Table 36. Global Acute Migraine Drugs Company, Product Type & Application Table 37. Global Acute Migraine Drugs Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Acute Migraine Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Acute Migraine Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Acute Migraine Drugs Sales by Region (2021-2026) & (K Unit) Table 42. Global Acute Migraine Drugs Sales Market Share in Volume by Region (2021-2026) Table 43. Global Acute Migraine Drugs Sales by Region (2021-2026) & (US$ Million) Table 44. Global Acute Migraine Drugs Sales Market Share in Value by Region (2021-2026) Table 45. Global Acute Migraine Drugs Sales (K Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 46. Global Acute Migraine Drugs Sales by Region (2027-2032) & (K Unit) Table 47. Global Acute Migraine Drugs Sales Market Share in Volume by Region (2027-2032) Table 48. Global Acute Migraine Drugs Sales by Region (2027-2032) & (US$ Million) Table 49. Global Acute Migraine Drugs Sales Market Share in Value by Region (2027-2032) Table 50. Global Acute Migraine Drugs Sales (K Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2027-2032) Table 51. Global Acute Migraine Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Acute Migraine Drugs Sales by Application (2021-2026) & (K Unit) Table 53. Global Acute Migraine Drugs Sales Market Share in Volume by Application (2021-2026) Table 54. Global Acute Migraine Drugs Sales by Application (2021-2026) & (US$ Million) Table 55. Global Acute Migraine Drugs Sales Market Share in Value by Application (2021-2026) Table 56. Global Acute Migraine Drugs Price by Application (2021-2026) & (USD/Unit) Table 57. Global Acute Migraine Drugs Sales by Application (2027-2032) & (K Unit) Table 58. Global Acute Migraine Drugs Sales Market Share in Volume by Application (2027-2032) Table 59. Global Acute Migraine Drugs Sales by Application (2027-2032) & (US$ Million) Table 60. Global Acute Migraine Drugs Sales Market Share in Value by Application (2027-2032) Table 61. Global Acute Migraine Drugs Price by Application (2027-2032) & (USD/Unit) Table 62. North America Acute Migraine Drugs Sales by Application (2021-2026) & (K Unit) Table 63. North America Acute Migraine Drugs Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Acute Migraine Drugs Sales by Application (2021-2026) & (K Unit) Table 65. Europe Acute Migraine Drugs Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Acute Migraine Drugs Sales by Application (2021-2026) & (K Unit) Table 67. Asia-Pacific Acute Migraine Drugs Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Acute Migraine Drugs Sales by Application (2021-2026) & (K Unit) Table 69. Latin America Acute Migraine Drugs Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Acute Migraine Drugs Sales by Application (2021-2026) & (K Unit) Table 71. Middle East and Africa Acute Migraine Drugs Sales by Application (2021-2026) & (US$ Million) Table 72. GSK Company Information Table 73. GSK Business Overview Table 74. GSK Acute Migraine Drugs Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 75. GSK Acute Migraine Drugs Product Portfolio Table 76. GSK Recent Development Table 77. Teva Company Information Table 78. Teva Business Overview Table 79. Teva Acute Migraine Drugs Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 80. Teva Acute Migraine Drugs Product Portfolio Table 81. Teva Recent Development Table 82. Pfizer Company Information Table 83. Pfizer Business Overview Table 84. Pfizer Acute Migraine Drugs Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 85. Pfizer Acute Migraine Drugs Product Portfolio Table 86. Pfizer Recent Development Table 87. Novartis Company Information Table 88. Novartis Business Overview Table 89. Novartis Acute Migraine Drugs Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 90. Novartis Acute Migraine Drugs Product Portfolio Table 91. Novartis Recent Development Table 92. Sun Pharma Company Information Table 93. Sun Pharma Business Overview Table 94. Sun Pharma Acute Migraine Drugs Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 95. Sun Pharma Acute Migraine Drugs Product Portfolio Table 96. Sun Pharma Recent Development Table 97. Grunenthal Company Information Table 98. Grunenthal Business Overview Table 99. Grunenthal Acute Migraine Drugs Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 100. Grunenthal Acute Migraine Drugs Product Portfolio Table 101. Grunenthal Recent Development Table 102. Endo Pharmaceuticals Company Information Table 103. Endo Pharmaceuticals Business Overview Table 104. Endo Pharmaceuticals Acute Migraine Drugs Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 105. Endo Pharmaceuticals Acute Migraine Drugs Product Portfolio Table 106. Endo Pharmaceuticals Recent Development Table 107. Merck Company Information Table 108. Merck Business Overview Table 109. Merck Acute Migraine Drugs Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 110. Merck Acute Migraine Drugs Product Portfolio Table 111. Merck Recent Development Table 112. J & J Company Information Table 113. J & J Business Overview Table 114. J & J Acute Migraine Drugs Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 115. J & J Acute Migraine Drugs Product Portfolio Table 116. J & J Recent Development Table 117. North America Acute Migraine Drugs Market Size Growth Rate (CAGR) by Country (K Unit): 2021 VS 2025 VS 2032 Table 118. North America Acute Migraine Drugs Sales by Country (2021-2026) & (K Unit) Table 119. North America Acute Migraine Drugs Sales Market Share by Country (2021-2026) Table 120. North America Acute Migraine Drugs Sales Forecast by Country (2027-2032) & (K Unit) Table 121. North America Acute Migraine Drugs Sales Market Share Forecast by Country (2027-2032) Table 122. North America Acute Migraine Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 123. North America Acute Migraine Drugs Market Size by Country (2021-2026) & (US$ Million) Table 124. North America Acute Migraine Drugs Market Share by Country (2021-2026) Table 125. North America Acute Migraine Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 126. North America Acute Migraine Drugs Market Share Forecast by Country (2027-2032) Table 127. Europe Acute Migraine Drugs Market Size Growth Rate (CAGR) by Country (K Unit): 2021 VS 2025 VS 2032 Table 128. Europe Acute Migraine Drugs Sales by Country (2021-2026) & (K Unit) Table 129. Europe Acute Migraine Drugs Sales Market Share by Country (2021-2026) Table 130. Europe Acute Migraine Drugs Sales Forecast by Country (2027-2032) & (K Unit) Table 131. Europe Acute Migraine Drugs Sales Market Share Forecast by Country (2027-2032) Table 132. Europe Acute Migraine Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 133. Europe Acute Migraine Drugs Market Size by Country (2021-2026) & (US$ Million) Table 134. Europe Acute Migraine Drugs Market Share by Country (2021-2026) Table 135. Europe Acute Migraine Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 136. Europe Acute Migraine Drugs Market Share Forecast by Country (2027-2032) Table 137. Asia-Pacific Acute Migraine Drugs Market Size Growth Rate (CAGR) by Country (K Unit): 2021 VS 2025 VS 2032 Table 138. Asia-Pacific Acute Migraine Drugs Sales by Country (2021-2026) & (K Unit) Table 139. Asia-Pacific Acute Migraine Drugs Sales Market Share by Country (2021-2026) Table 140. Asia-Pacific Acute Migraine Drugs Sales Forecast by Country (2027-2032) & (K Unit) Table 141. Asia-Pacific Acute Migraine Drugs Sales Market Share Forecast by Country (2027-2032) Table 142. Asia-Pacific Acute Migraine Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 143. Asia-Pacific Acute Migraine Drugs Market Size by Country (2021-2026) & (US$ Million) Table 144. Asia-Pacific Acute Migraine Drugs Market Share by Country (2021-2026) Table 145. Asia-Pacific Acute Migraine Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 146. Asia-Pacific Acute Migraine Drugs Market Share Forecast by Country (2027-2032) Table 147. Latin America Acute Migraine Drugs Market Size Growth Rate (CAGR) by Country (K Unit): 2021 VS 2025 VS 2032 Table 148. Latin America Acute Migraine Drugs Sales by Country (2021-2026) & (K Unit) Table 149. Latin America Acute Migraine Drugs Sales Market Share by Country (2021-2026) Table 150. Latin America Acute Migraine Drugs Sales Forecast by Country (2027-2032) & (K Unit) Table 151. Latin America Acute Migraine Drugs Sales Market Share Forecast by Country (2027-2032) Table 152. Latin America Acute Migraine Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 153. Latin America Acute Migraine Drugs Market Size by Country (2021-2026) & (US$ Million) Table 154. Latin America Acute Migraine Drugs Market Share by Country (2021-2026) Table 155. Latin America Acute Migraine Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 156. Latin America Acute Migraine Drugs Market Share Forecast by Country (2027-2032) Table 157. Middle East and Africa Acute Migraine Drugs Market Size Growth Rate (CAGR) by Country (K Unit): 2021 VS 2025 VS 2032 Table 158. Middle East and Africa Acute Migraine Drugs Sales by Country (2021-2026) & (K Unit) Table 159. Middle East and Africa Acute Migraine Drugs Sales Market Share by Country (2021-2026) Table 160. Middle East and Africa Acute Migraine Drugs Sales Forecast by Country (2027-2032) & (K Unit) Table 161. Middle East and Africa Acute Migraine Drugs Sales Market Share Forecast by Country (2027-2032) Table 162. Middle East and Africa Acute Migraine Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 163. Middle East and Africa Acute Migraine Drugs Market Size by Country (2021-2026) & (US$ Million) Table 164. Middle East and Africa Acute Migraine Drugs Market Share by Country (2021-2026) Table 165. Middle East and Africa Acute Migraine Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 166. Middle East and Africa Acute Migraine Drugs Market Share Forecast by Country (2027-2032) Table 167. Key Raw Materials Table 168. Raw Materials Key Suppliers Table 169. Acute Migraine Drugs Distributors List Table 170. Acute Migraine Drugs Customers List Table 171. Research Programs/Design for This Report Table 172. Authors List of This Report Table 173. Secondary Sources Table 174. Primary Sources List of Figures Figure 1. Acute Migraine Drugs Image Figure 2. Global Acute Migraine Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Acute Migraine Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Acute Migraine Drugs Sales (2021-2032) & (K Unit) Figure 5. Triptans Image Figure 6. Global Triptans Sales YoY Growth (2021-2032) & (K Unit) Figure 7. NSAIDs Image Figure 8. Global NSAIDs Sales YoY Growth (2021-2032) & (K Unit) Figure 9. Others Image Figure 10. Global Others Sales YoY Growth (2021-2032) & (K Unit) Figure 11. Global Acute Migraine Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Acute Migraine Drugs Market Share by Type 2025 VS 2032 Figure 13. North America Acute Migraine Drugs Sales Market Share in Volume by Type in 2025 Figure 14. North America Acute Migraine Drugs Sales Market Share in Value by Type in 2025 Figure 15. Europe Acute Migraine Drugs Sales Market Share in Volume by Type in 2025 Figure 16. Europe Acute Migraine Drugs Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Acute Migraine Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Acute Migraine Drugs Sales Market Share in Value by Type in 2025 Figure 19. Latin America Acute Migraine Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Acute Migraine Drugs Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Acute Migraine Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Acute Migraine Drugs Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Acute Migraine Drugs Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Hospital Pharmacies Image Figure 26. Global Hospital Pharmacies Sales YoY Growth (2021-2032) & (K Unit) Figure 27. Drug Stores Image Figure 28. Global Drug Stores Sales YoY Growth (2021-2032) & (K Unit) Figure 29. Global Acute Migraine Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Acute Migraine Drugs Market Share by Application 2025 VS 2032 Figure 31. North America Acute Migraine Drugs Sales Market Share in Volume by Application in 2025 Figure 32. North America Acute Migraine Drugs Sales Market Share in Value by Application in 2025 Figure 33. Europe Acute Migraine Drugs Sales Market Share in Volume by Application in 2025 Figure 34. Europe Acute Migraine Drugs Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Acute Migraine Drugs Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Acute Migraine Drugs Sales Market Share in Value by Application in 2025 Figure 37. Latin America Acute Migraine Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Acute Migraine Drugs Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Acute Migraine Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Acute Migraine Drugs Sales Market Share in Value by Application in 2025 Figure 41. North America Acute Migraine Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Unit) Figure 42. North America Acute Migraine Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Acute Migraine Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Acute Migraine Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Acute Migraine Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Unit) Figure 46. Europe Acute Migraine Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Acute Migraine Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Acute Migraine Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Acute Migraine Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Unit) Figure 50. Asia-Pacific Acute Migraine Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Acute Migraine Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Acute Migraine Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Acute Migraine Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Unit) Figure 54. Latin America Acute Migraine Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Acute Migraine Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Acute Migraine Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Acute Migraine Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Unit) Figure 58. Middle East and Africa Acute Migraine Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Acute Migraine Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Acute Migraine Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Acute Migraine Drugs Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Acute Migraine Drugs Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Triptans
  • NSAIDs
  • Others
Applications
  • Hospital Pharmacies
  • Drug Stores
Companies covered
  • GSK
  • Teva
  • Pfizer
  • Novartis
  • Sun Pharma
  • Grunenthal
  • Endo Pharmaceuticals
  • Merck
  • J & J

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Acute Migraine Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Acute Migraine Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Acute Migraine Drugs Market by Type
  6. 1.3.1 Triptans
  7. 1.3.2 NSAIDs
  8. 1.3.3 Others
  9. 1.4 Global Acute Migraine Drugs Market Size by Type
  10. 1.4.1 Global Acute Migraine Drugs Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Acute Migraine Drugs Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Acute Migraine Drugs Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Acute Migraine Drugs Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Acute Migraine Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Acute Migraine Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Acute Migraine Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Acute Migraine Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Acute Migraine Drugs Industry Trends
  2. 2.2 Acute Migraine Drugs Industry Drivers
  3. 2.3 Acute Migraine Drugs Industry Opportunities and Challenges
  4. 2.4 Acute Migraine Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Acute Migraine Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Acute Migraine Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Acute Migraine Drugs Price (2021-2026)
  4. 3.4 Global Acute Migraine Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Acute Migraine Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Acute Migraine Drugs Company, Product Type & Application
  7. 3.7 Global Acute Migraine Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Acute Migraine Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Acute Migraine Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Acute Migraine Drugs Tier 1, Tier 2, and Tier 3
4 Acute Migraine Drugs Regional Status and Outlook
  1. 4.1 Global Acute Migraine Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Acute Migraine Drugs Historic Market Size by Region
  3. 4.2.1 Global Acute Migraine Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Acute Migraine Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Acute Migraine Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Acute Migraine Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Acute Migraine Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Acute Migraine Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Acute Migraine Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Acute Migraine Drugs by Application
  1. 5.1 Acute Migraine Drugs Market by Application
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Drug Stores
  4. 5.2 Global Acute Migraine Drugs Market Size by Application
  5. 5.2.1 Global Acute Migraine Drugs Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Acute Migraine Drugs Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Acute Migraine Drugs Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Acute Migraine Drugs Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Acute Migraine Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Acute Migraine Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Acute Migraine Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Acute Migraine Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 GSK
  2. 6.1.1 GSK Company Information
  3. 6.1.2 GSK Business Overview
  4. 6.1.3 GSK Acute Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 GSK Acute Migraine Drugs Product Portfolio
  6. 6.1.5 GSK Recent Developments
  7. 6.2 Teva
  8. 6.2.1 Teva Company Information
  9. 6.2.2 Teva Business Overview
  10. 6.2.3 Teva Acute Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Teva Acute Migraine Drugs Product Portfolio
  12. 6.2.5 Teva Recent Developments
  13. 6.3 Pfizer
  14. 6.3.1 Pfizer Company Information
  15. 6.3.2 Pfizer Business Overview
  16. 6.3.3 Pfizer Acute Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Pfizer Acute Migraine Drugs Product Portfolio
  18. 6.3.5 Pfizer Recent Developments
  19. 6.4 Novartis
  20. 6.4.1 Novartis Company Information
  21. 6.4.2 Novartis Business Overview
  22. 6.4.3 Novartis Acute Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Novartis Acute Migraine Drugs Product Portfolio
  24. 6.4.5 Novartis Recent Developments
  25. 6.5 Sun Pharma
  26. 6.5.1 Sun Pharma Company Information
  27. 6.5.2 Sun Pharma Business Overview
  28. 6.5.3 Sun Pharma Acute Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Sun Pharma Acute Migraine Drugs Product Portfolio
  30. 6.5.5 Sun Pharma Recent Developments
  31. 6.6 Grunenthal
  32. 6.6.1 Grunenthal Company Information
  33. 6.6.2 Grunenthal Business Overview
  34. 6.6.3 Grunenthal Acute Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Grunenthal Acute Migraine Drugs Product Portfolio
  36. 6.6.5 Grunenthal Recent Developments
  37. 6.7 Endo Pharmaceuticals
  38. 6.7.1 Endo Pharmaceuticals Company Information
  39. 6.7.2 Endo Pharmaceuticals Business Overview
  40. 6.7.3 Endo Pharmaceuticals Acute Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Endo Pharmaceuticals Acute Migraine Drugs Product Portfolio
  42. 6.7.5 Endo Pharmaceuticals Recent Developments
  43. 6.8 Merck
  44. 6.8.1 Merck Company Information
  45. 6.8.2 Merck Business Overview
  46. 6.8.3 Merck Acute Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Merck Acute Migraine Drugs Product Portfolio
  48. 6.8.5 Merck Recent Developments
  49. 6.9 J & J
  50. 6.9.1 J & J Company Information
  51. 6.9.2 J & J Business Overview
  52. 6.9.3 J & J Acute Migraine Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 J & J Acute Migraine Drugs Product Portfolio
  54. 6.9.5 J & J Recent Developments
7 North America by Country
  1. 7.1 North America Acute Migraine Drugs Sales by Country
  2. 7.1.1 North America Acute Migraine Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Acute Migraine Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Acute Migraine Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Acute Migraine Drugs Market Size by Country
  6. 7.2.1 North America Acute Migraine Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Acute Migraine Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Acute Migraine Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Acute Migraine Drugs Sales by Country
  2. 8.1.1 Europe Acute Migraine Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Acute Migraine Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Acute Migraine Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Acute Migraine Drugs Market Size by Country
  6. 8.2.1 Europe Acute Migraine Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Acute Migraine Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Acute Migraine Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Acute Migraine Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Acute Migraine Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Acute Migraine Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Acute Migraine Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Acute Migraine Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Acute Migraine Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Acute Migraine Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Acute Migraine Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Acute Migraine Drugs Sales by Country
  2. 10.1.1 South America Acute Migraine Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Acute Migraine Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Acute Migraine Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Acute Migraine Drugs Market Size by Country
  6. 10.2.1 South America Acute Migraine Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Acute Migraine Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Acute Migraine Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Acute Migraine Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Acute Migraine Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Acute Migraine Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Acute Migraine Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Acute Migraine Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Acute Migraine Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Acute Migraine Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Acute Migraine Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Acute Migraine Drugs Value Chain Analysis
  2. 12.1.1 Acute Migraine Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Acute Migraine Drugs Production Mode & Process
  7. 12.2 Acute Migraine Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Acute Migraine Drugs Distributors
  10. 12.2.3 Acute Migraine Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst